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Abstract
The transient dermal exposure is one where the skin is exposed to chemical for a finite duration, 
after which the chemical is removed and no residue remains on the skin’s surface. Chemical 
within the skin at the end of the exposure period can still enter the systemic circulation. If it has 
some volatility, a portion of it will evaporate from the surface before it has a chance to be 
absorbed by the body. The fate of this post-exposure “skin depot” is the focus of this theoretical 
study. Laplace domain solutions for concentration distribution, flux, and cumulative mass 
absorption and evaporation are presented, and time domain results are obtained through numerical 
inversion. The Final Value Theorem is applied to obtain the analytical solutions for the total 
fractional absorption by the body and evaporation from skin at infinite time following a transient 
exposure. The solutions depend on two dimensionless variables: χ, the ratio of evaporation rate to 
steady-state dermal permeation rate; and the ratio of exposure time to membrane lag time. Simple 
closed form algebraic equations are presented that closely approximate the complete analytical 
solutions. Applications of the theory to the dermal risk assessment of pharmaceutical, 
occupational, and environmental exposures are presented for four example chemicals.
Keywords
absorption potential; transdermal; passive diffusion/transport; percutaneous; skin; solvent 
evaporation
INTRODUCTION
Recent analyses have advanced our understanding of the absorption of chemicals in contact 
with skin from finite dose1–5 and transient exposures.6,7 The former is characterized as an 
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exposure to a small (finite) dose (mass/area) of chemical, the disposition of which has been 
shown to depend on the relative rates of evaporation and permeation as well as the initial 
load. The finite dose is a good model for splash-type exposures in the workplace and also for 
pharmaceutical and cosmetic product applications. The transient exposure is one where the 
skin is exposed to chemical for a finite duration, after which the chemical is removed and no 
residue remains atop the surface. Chemical within the skin at the end of the exposure period 
can still enter the systemic circulation. If it has some volatility, a portion of it will evaporate 
from the skin surface before it has a chance to be absorbed by the body. As an example that 
is relevant to dermal risk assessment, consider bathing or showering with contaminated 
water. Dermal absorption proceeds for the duration of the exposure, but once the bath or 
shower has ended, contaminant residing within the skin may still be absorbed by the body 
while some may evaporate into the surrounding air. The fate of this post-exposure “skin 
depot” is the focus of this theoretical study.
Frasch and Barbero7 provided analytical solutions for total mass absorbed by the body 
(exposure duration plus post-exposure) for the extreme cases of non-volatile and infinitely 
volatile chemicals. N’Dri-Stempfer and Bunge6 presented finite difference post-transient 
exposure solutions for chemicals of varying volatility. Based on the numerical results, they 
derived a four-parameter empirical equation to predict post-exposure evaporation expressed 
as a fraction of the mass residing within the membrane at the conclusion of the exposure 
time. Herein, we derive the complete analytical solutions for fractional absorption by the 
body and evaporation from skin for variable volatility. In this study, as in previous ones, the 
skin is considered to be a single pseudo-homogeneous membrane.
THEORY
It is assumed here that the skin is transiently exposed to a (possibly) volatile chemical. At 
the end of the exposure period, the skin is efficiently decontaminated such that zero residual 
chemical remains on the surface. We wish to determine the disposition of chemical residing 
within the skin following this exposure.
With the exception of highly lipophilic chemicals, the main barrier property of the skin is 
imparted by the stratum corneum (SC). In its simplest form, the SC may be considered to be 
a uniform effective medium of thickness h, occupying the space between x = 0 (the skin 
surface) and x = h (bottom of tissue). The permeant has an effective diffusivity D that does 
not vary with position or time. This implies that neither the permeant nor its vehicle alter the 
SC permeability. The SC, initially free of chemical, is exposed to a constant concentration in 
vehicle Cv for a specified duration texp. It is assumed that the chemical does not bind to the 
SC and that the dermal vasculature acts as a perfect sink at the bottom of the tissue.
With these stipulations, post-exposure (t ≥ texp) permeant transport is governed by the one-
dimensional diffusion equation:
(1)
with the initial condition:
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The parameter χ is the dimensionless ratio of the evaporation rate to the steady-state dermal 
absorption rate of the permeant, and is discussed in detail elsewhere.2,6 Physically, χ 
describes the post-exposure conditions at the skin surface and its value, depending on the 
situation, can vary from zero, representing zero flux from the skin surface, to infinity, which 
corresponds to zero concentration (sink conditions) on the skin surface. In addition to 
representing chemicals that evaporate rapidly from the skin surface, χ → ∞ mathematically 
describes a situation in which a chemical is removed from the skin with a continuous rinse 
or solvent immersion. In instances where chemical volatility is equated with χ in this 
manuscript, it is understood that volatility is relative to the dermal absorption rate. Any two 
chemicals may have similar evaporation rates, but χ will differ if the dermal absorption rates 
differ.
The initial concentration distribution specified by Eq. (2) is given by Crank.8 Note that the 
initial mass (per unit area) within the SC, that is, the total mass at the end of the exposure 
time, is:
(5)
where the permeability coefficient kp = KmvD/h.
METHODS
The solution of Eq. (1) with associated initial and boundary conditions was undertaken using 
the method of Laplace transforms. Solutions for concentration distribution, flux, and 
cumulative mass absorption and evaporation are presented. Time domain solutions were 
obtained through numerical inversion of the Laplace domain equations using Scientist 
(MicroMath Scientific Software, St. Louis, Missouri). The Final Value Theorem was applied 
to obtain total cumulative mass absorption and evaporation at infinite time postexposure, 
expressed as fractions of the total mass within the skin at the end of the exposure time. 
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Simple closed form algebraic equations are presented that closely approximate the complete 
analytical solutions. For practical applications, the time it takes for the body to absorb 90% 
of the total infinite-time amount was estimated.
RESULTS
The Laplace transform of Eq. (1) is:
(6)
with the hat (ˆ) indicating a function of the Laplace variable s, and . The Laplace 
transform of Eq. (3) is:
(7)




where kn = nπ/h, and
(10)
Ĉp (x, s) is the particular solution to Eq. (6). Its value depends on the specific form taken by 
the nonhomogeneous terms (here, −C0(x)/D). Tables of solutions are available in a number 
of sources (e.g., the CRC Standard Mathematical Tables9).
Figure 1 shows plots of C(x, t) within the membrane for various values of χ. The plots 
represent inverse Laplace transforms of Eq. (8). For small χ, there is little evaporation and 
the chemical concentration is greatest at the skin surface. The time to clear chemical from 
the SC is relatively long. For large χ, most of the chemical within the skin at the end of the 
exposure evaporates. Chemical concentration is greatest in the mid to upper portions of the 
skin, and the clearance time is relatively short.
In the Laplace domain, the flux is given by:
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The cumulative mass absorption by the body (mass/area) is given by:
(13)
and the cumulative mass evaporation from the skin surface is given by:
(14)
The convention that the x axis points into the skin necessitates the minus sign in Eq. (14) 
because efflux from the skin by evaporation corresponds to transport in the −x direction.
Figure 2 shows plots of normalized absorption by the body over time (mabs(t)/ m0) and 
evaporation from the surface (mevap (t) /m0) for several values of χ when texp/tlag = 0.6. Plots 
were obtained from the inverse Laplace transforms of Eqs. (13) and (14), both divided by 
Eq. (5). For a poorly volatile permeant (small χ), nearly all of the chemical within the skin at 
the end of the exposure time is eventually absorbed by the body. For highly volatile 
compounds (large χ), evaporation is substantial and under the exposure conditions shown in 
Figure 2, only about 27% of the initial skin amount is absorbed. Compared with a small χ 
permeant, the time to completely distribute the chemical from the SC is shorter.
The total amount absorbed by the body (per area), after infinite time may be calculated from 
the Final Value Theorem:
(15)
The result is given here as the fraction of the initial amount present in the membrane at the 
end of the exposure duration (Eq. (5)) that absorbs into the body:
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At infinite time, all permeant has either been absorbed or evaporated. Therefore, the fraction 
that evaporates is:
(17)
Detailed solutions are available as Supplementary Materials (Part 1). Note that the limits for 
long exposure times (texp ≫ tlag) are:
(18)
(19)
Thus, the fraction of what is in the skin following a long exposure that absorbs into the body 
is between 1/3, for a highly volatile chemical, and one, for a non-volatile chemical.
Figure 3 shows the solutions to Eqs. (16) and (17) for the first 100 terms in the series, for 
which the quantities are independent of the number of terms to at least six significant figures 
for texp/tlag ≥ 0.001. For a poorly volatile permeant (small χ), nearly all of the chemical 
within the skin at the end of the exposure time is eventually absorbed by the body; this 
outcome is independent of exposure time. For χ < 0.1, less than 10% of the amount in the 
skin evaporates. As χ increases, evaporation becomes important and for highly volatile 
chemicals, at least 2/3 of the chemical in the skin at the end of the exposure evaporates. For 
highly volatile compounds, the total absorbed and evaporated fractions depend on the 
exposure time: Fabs varies from zero for small values of texp/tlag to a maximum of one-third 
for large values of texp/tlag.
Equations (16) and (17) are somewhat cumbersome, although they may readily be 
approximated to a finite number of terms using commercially available mathematical 
software packages (e.g., Mathcad or even Excel). The presence of infinite series in the 
equations is a consequence of the initial concentration distribution of permeant (Eq. (2)). 
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Because of the complexity of these equations, simple algebraic approximations were sought 
empirically. The following one-parameter equations were explored:
(20)
(21)
Nonlinear regression with the 100-term series solutions yielded a value of 2.906 for a1. The 
correlation coefficient R2 > 0.98, but the differences are largest for small texp/tlag. Numerical 
comparisons were made to investigate errors of using the simple Fabs equation. The estimate 
for Fabs provided by the Eq. (20) approximation should be within 10% of the exact value if:
(22)
Consequently, Eqs. (20) and (21) (with a1 as specified) may be used with confidence in lieu 
of the full series solutions, with the proviso implied by Eq. (22). Additional information on 
the numerical comparisons leading to Eq. (22) is presented in Supplementary Materials (Part 
2).
In any realistic setting, infinite time is of course an abstraction. A practical application may 
require an estimate of the time it takes for the body to absorb most of the final quantity. 
Figure 4 shows the time after the exposure ends to reach 90% of the final quantity absorbed 
by the body (t90%). There is a weak dependence on texp/tlag: all intermediate values fell 
within the displayed values of 0.05 and 100. The time it takes for nearly complete absorption 
ranges from about 6 × tlag for poorly volatile compounds to about 2 × tlag for highly volatile 
ones. The pooled data were fitted to the following three-parameter decay curve:
(23)
Parameter values for the solid curve displayed in Figure 4 are: a2 = 1.895, b2 = 3.856, c2 = 
0.698; the global R2 > 0.97.
The figure confirms and quantifies what is shown in Figure 2: for large χ, the time to 
distribute almost all of the chemical from the SC is shorter than that for small χ. For a poorly 
volatile chemical, surface evaporation is insignificant and most chemical within the skin 
must diffuse inward into the body. The chemical is concentrated at the skin surface (Fig. 1) 
and so the overall time to complete absorption is relatively longer. For large χ, most of the 
chemical within the skin at the end of the exposure evaporates. Chemical concentration is 
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greatest in the mid to upper portions of the skin (Fig. 1). Rapid evaporation clears this 
permeant and the overall time to complete dermal absorption is shorter.
DISCUSSION
The solutions presented here for Fabs and Fevap refer to the post-exposure absorbed and 
evaporated fractions of the amount of permeant present in the membrane at the end of the 
exposure time (t = texp). In many instances, it would be desirable to estimate the total 
amount of permeant that has been absorbed into the body from the entire transient exposure. 
For example, dermal risk assessments of exposures to occupational chemicals, 
environmental contaminants, cosmetic and consumer products, as well as pharmaceutical 
compound applications, require such estimates.
The total mass absorbed (mT, mass/area) is given by:
(24)
where mabs(texp) is the mass that has been absorbed into the body at t = texp10:
(25)
Fabs is given by Eq. (16), and m0 by Eq. (5). Frasch and Barbero7 derived solutions for mT 
(m∞ in their terminology) for the special cases of χ = ∞ (their Case 1) and χ = 0 (Case 2). 
Note that mT may be estimated with quantities commonly measured from standard in vitro 
diffusion cell experiments, specifically kp and tlag. Other required parameters are chemical 
concentration, exposure duration and χ. Kasting and Miller2 provide equations to estimate χ 
based on known or measurable chemical properties including vapor pressure, molecular 
weight, octanol–water partition coefficient, and water solubility. Alternatively, χ may be 
measured directly under controlled conditions. Gajjar et al.11 provide data on the 
evaporation rates of 21 volatile organic compounds from films of neat liquid on human skin, 
which may be combined with measured or estimated steady-state dermal flux of the 
compounds from a solution at unit activity (i.e., either neat or in a saturated solution) to 
obtain χ.
A strategy such as outlined in this paper could be used to identify chemical and exposure 
situations for which chemical in the SC is or is not likely to be systemically absorbed. 
Current practices vary on whether chemical in skin at the end of an exposure should or 
should not be included in estimates of the systemically absorbed.12 For example, risk 
assessment guidance documents from the USEPA,13 OECD,14–16 and ECETOC17 identify 
chemical left after washing the exposed skin, including the entire SC, as absorbable but not 
absorbed. In contrast, the European Commission18 and USEPA in the final test rule for in 
vitro dermal penetration rate testing issued in 200419 consider chemical in the SC and 
deeper skin layers as absorbed. European guidance for cosmetics and consumer products 
exclude chemical in the SC from estimates of the absorbed dose,20–24 whereas the EFSA25 
specifies that chemical in all but the first two tape strips should be classified as absorbed 
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unless it can be shown that remaining chemical is not bioavailable or that >75% of the 
material in the receptor solution (or systemically absorbed in an in vivo study) occurred 
within half of the duration of the sampling time.
In Tables 1 and 2, we illustrate the use of the method by calculating Fabs, m0, mT, and the 
fraction of mT that is absorbed postexposure (Fabs × m0/mT). Table 1 contains the chemical 
and skin permeation properties for four example chemicals, and Table 2 contains calculated 
values for skin exposures of 5 min, 1 h, and much longer than tlag. The chosen chemicals are 
important components in dermatological, cosmetic, and consumer products (ethanol, 
diphenylamine), produced and used in large quantities in the United States (p-nitrophenol 
and diphenylamine), and a commonly used plasticizer (benzylbutylphthalate). They illustrate 
a range of evaporation and skin penetration rates, giving small and large estimates for χ. 
Disposition of chemical in the SC at the end of the exposure was calculated assuming the 
skin was either left open to the air or immersed in a liquid solution with a large saturation 
concentration for the chemical. Washout into a liquid solution corresponds to χ approaching 
infinity, which was approximated with χ = 1000. The absorption fraction (Eq. (16)) and 
absorbed masses (Eq. (24)) have been calculated using the first 20 terms of the series, which 
were sufficient for the solutions to be independent of the number of terms to three 
significant digits. Fractional absorption was also calculated using the simple approximation 
represented by Eq. (20). The quantities differ most for small values of Fabs, but overall the 
agreement is excellent. The absorbed masses were calculated assuming an exposed area of 
180 cm2, equivalent to the area of the palm of one hand,26 and a vehicle concentration equal 
to the chemical’s aqueous saturation value; that is, the calculations were made using 
estimates of maximum flux conditions. The time for 90% of the ultimate absorption of 
chemical within the skin at the end of exposure (Eq. (23)) is also listed. An Excel 
spreadsheet was developed to perform these calculations; it is available for use in 
Supplementary Materials (Part 4).
The absorption fraction is smallest for volatile chemicals with short exposure times relative 
to the lag time. Thus, although ethanol is much more volatile than diphenylamine, almost the 
same fraction of diphenylamine and ethanol absorbs after a 5 min exposure because the ratio 
of exposure time to lag time is smaller for diphenylamine. However, because its lag time is 
larger than ethanol’s, 90% absorption of diphenylamine takes four times longer than ethanol 
(2.7 compared with 0.6 h). Evaporation of compounds with low vapor pressure can occur if 
the skin permeation rate is slow. Benzylbutylphthalate is a low vapor pressure example in 
which the estimate for χ = 0.48 and 21% is predicted to evaporate, although 41 h are 
required.
For the chemicals listed in Table 2, at least 85% of the total absorbed mass is absorbed after 
the exposure for exposure durations up to 0.78 × tlag. Thus, mT will depend strongly on Fabs 
(and hence χ). For skin exposed to air following a 5 min exposure to p-nitroaniline, (small χ, 
large Fabs), nearly all of the skin depot (m0) is eventually absorbed. If the skin is exposed to 
liquid (large χ, small Fabs), mT is only about 10% that of the air-exposed skin but in both 
cases, nearly all of the absorption occurs postexposure. As texp/tlag increases, a greater 
proportion of mT occurs within the exposure duration. For a 1 h ethanol exposure, about 
30% of the total absorption occurs postexposure; this percentage would increase for a 
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chemical with less volatility. Even for exposures of 10 × tlag, at least 10% of the total 
absorption occurs postexposure, and this post-exposure amount may exceed the total 
absorbed amount for shorter exposures. These results support the consideration of skin depot 
amounts in estimates of the systemically absorbed amount. Theoretically, two-thirds or more 
of all the chemicals could be washed out of the skin with a suitable solvent, although, except 
for ethanol, the time required would be unrealistically large (2.4 or more hours).
Strong chemical binding to skin components and desquamation of the skin would also 
prevent systemic absorption of chemical from the SC and skin. Because turnover of the SC 
occurs over many days, it is only important for chemicals that are strongly bound or slowly 
permeating as shown by diffusion modeling similar to that described here for 
evaporation.39,40 Based on these model results, the USEPA risk assessment guidance for 
dermal absorption considers the effect of desquamation.41
This manuscript provides a theoretical framework for transient dermal exposures to volatile 
chemicals that do not bind to the membrane or substantially impact skin permeability. With 
the results presented here, combined with previous studies, substantial progress has been 
made in our understanding of the disposition of chemicals from both finite and transient 
dose dermal exposures. Analytical expressions for fractional absorption and evaporation 
have previously been presented for the finite dose case.5 The current work provides 
corresponding expressions for the transient exposure. A logical next step might be the 
inclusion of binding of compounds to skin components.42,43 The theory should be tested by 
controlled in vitro experiments using skin or artificial membranes.7
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Dimensionless concentration distributions at relative positions within the membrane for 
varying times after an exposure of texp/tlag = 0.6. Different values of χ are shown, 
representing non-volatile (χ = 0.001), semivolatile (χ = 1, 10), and highly volatile (χ = 100) 
compounds. Plots represent inverse Laplace transforms of Eq. (8).
FRASCH and BUNGE Page 13














Mass absorption into the body (top) and mass evaporation from the skin surface (bottom) 
over time following an exposure of texp/tlag = 0.6 for various values of χ. Plots represent 
inverse Laplace transforms of Eqs. (13) and (14), normalized by Eq. (5).
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The fractions of chemical in the skin at the end of exposure that will be absorbed (Fabs) and 
evaporated (Fevap). Plots represent 100 terms of Eqs. (16) and (17). Insets: Fabs and Fevap for 
smaller values of χ.
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Time after the exposure ends to reach 90% of the final quantity absorbed by the body (t90%). 
Solid line is a three-parameter exponential decay curve with parameter values, listed in the 
text, fitted to the pooled data.
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